- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
John Theurer Cancer Center, Hackensack University Medical Center | Strategic Alliance Partners
ABOUT HACKENSACK UNIVERSITY MEDICAL CENTER
Hackensack University Medical Center, a 803-bed nonprofit teaching and research hospital, was Bergen County’s first hospital founded in 1888. It was also the first hospital in New Jersey and second in the nation to become a Magnet®-recognized hospital for nursing excellence, receiving its sixth consecutive designation from the American Nurses Credentialing Center. The academic flagship of the Hackensack Meridian Health network, Hackensack University Medical Center is Nationally-Ranked by U.S. News & World Report 2022-2023 in four specialties, more than any other hospital in New Jersey. The hospital is home to the state's only nationally-ranked Urology and Neurology & Neurosurgery programs, as well as the best Cardiology & Heart Surgery program. It also offers patients nationally-ranked Orthopedic care and one of the state’s premier Cancer Centers (John Theurer Cancer Center at Hackensack University Medical Center). Hackensack University Medical Center also ranked as High-Performing in conditions such as Acute Kidney Failure, Heart Attack (AMI), Heart Failure, Pneumonia, chronic obstructive pulmonary disease (COPD), Diabetes and Stroke. As well as High Performing in procedures like Aortic Valve Surgery, Heart Bypass Surgery (CABG), Colon Cancer Surgery, Lung Cancer Surgery, Prostate Cancer Surgery, Hip Replacement and Knee Replacement. Named to Newsweek’s World’s Best Hospitals 2023 list, Hackensack University Medical Center is also the recipient of the 2023 Patient Safety Excellence Award™ by Healthgrades as well as an “A” Hospital Safety Grade from The Leapfrog Group. This award-winning care is provided on a campus that is home to facilities such as the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Women’s and Children’s Pavilion, which houses the Donna A. Sanzari Women’s Hospital and the Joseph M. Sanzari Children’s Hospital, ranked #1 in the state and top 20 in the Mid-Atlantic Region in the U.S. News & World Report’s 2022-23 Best Children’s Hospital Report. Additionally, the children’s nephrology program ranks in the top 50 in the United States. Hackensack University Medical Center is also home to the Deirdre Imus Environmental Health Center and is listed on the Green Guide’s list of Top 10 Green Hospitals in the U.S. Our comprehensive clinical research portfolio includes studies focused on precision medicine, translational medicine, immunotherapy, cell therapy, and vaccine development. The hospital has embarked on the largest healthcare expansion project ever approved by the state: Construction of the Helena Theurer Pavilion, a 530,000-sq.-ft., nine-story building, which began in 2019. A $714.2 million endeavor, the pavilion is one the largest healthcare capital projects in New Jersey and will house 24 state-of-the-art operating rooms with intraoperative MRI capability, 50 ICU beds, and 175 medical/surgical beds including a 50 room Musculoskeletal Institute.
Latest from John Theurer Cancer Center, Hackensack University Medical Center
JTCC and Georgetown’s Alliance in Cancer Research Achieves New Level With Immunotherapy Breakthrough
November 04, 2020
Article
It was 5:00 PM on a Monday, and Andrew Pecora, MD, FACP, CPE, was just wrapping up his practice for the day when one of his nurses came to the door, asking if he could see one more patient.
Meet the New Chief: McCloskey Takes Helm at John Theurer Cancer Center’s Leukemia Division
October 15, 2020
Article
As James K. McCloskey II, MD, begins the next chapter of his career as chief of the Division of Leukemia at John Theurer Cancer Center at Hackensack University Medical Center.
Hackensack University Medical Center Urologists Offer Pioneering Clinical Trial to Study Nerve Recovery after Robotic Prostatectomy for Prostate Cancer
October 12, 2020
Article
Department of Urology uses bioregenerative medicine to improve erectile function and continence after robotic radical prostatectomy.
Dr. Vesole on the Advantages of CAR T-Cell Therapy in Multiple Myeloma
October 05, 2020
Video
David H. Vesole, MD, PhD, discusses the advantages of CAR T-cell therapy in multiple myeloma.
Dr. Goy on the Utility of NGS in Identifying Aggressive MCL Subtypes
October 01, 2020
Video
Andre Goy, MD, MS, discusses the utility of next-generation sequencing in identifying aggressive subtypes of mantle cell lymphoma.
Monoclonal Antibodies, ADCs, and CAR T Cells Invigorate the Myeloma Paradigm
September 29, 2020
Article
David H. Vesole, MD, PhD, discusses the evolution of multiple myeloma treatment, and explained how other BCMA-therapies are poised to impact clinical practice.
Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCL
September 28, 2020
Video
Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.
Dr. Leslie on Sequencing Zanubrutinib in MCL
September 23, 2020
Video
Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses sequencing strategies with zanubrutinib in mantle cell lymphoma.
Dr. Leslie on the Need for Clinical Trials to Address Unmet Needs in MCL
September 16, 2020
Video
Lori A. Leslie, MD, discusses the importance of clinical trials in finding novel, up-front therapy options for patients with mantle cell lymphoma.
Dr. Leslie on the Role of Zanubrutinib in MCL
September 14, 2020
Video
Lori A. Leslie, MD, discusses the role of zanubrutinib in mantle cell lymphoma.
Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies
September 09, 2020
Video
Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.
Dr. Leslie on Emerging Therapies in MCL
September 03, 2020
Video
Lori A. Leslie, MD, lymphoma attending, discusses emerging therapies in mantle cell lymphoma.
Emerging Approaches Seek to Expand the Relapsed/Refractory Follicular Lymphoma Treatment Arsenal
August 28, 2020
Article
Lori A. Leslie discusses several key studies evaluating emerging approaches in the relapsed/refractory follicular lymphoma paradigm.
Dr. Leslie on Frontline Treatment Options in Follicular Lymphoma
August 24, 2020
Video
Lori A. Leslie, MD, lymphoma attending, discusses frontline treatment options in follicular lymphoma.
Dr. Leslie on Phase 1b Trial of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma
August 22, 2020
Video
Lori A. Leslie, MD, discusses a phase 1b study with tazemetostat plus lenalidomide and rituximab in patients with follicular lymphoma.
John Theurer Cancer Center Investigators Participated in ZUMA-2 Study Leading to FDA Approval of First CAR T-Cell Therapy for Recurrent/Persistent Mantle Cell Lymphoma
August 04, 2020
Article
Investigators from John Theurer Cancer Center participated in the pivotal ZUMA-2 clinical trial, which assessed the safety and effectiveness of brexucabtagene autoleucel in patients with relapsed or refractory mantle cell lymphoma.
Calling Attention to Treatment Considerations in MCL
July 22, 2020
Article
Lori A. Leslie, MD, discusses the current treatment landscape in mantle cell lymphoma, factors to consider when selecting between BTK inhibitors, and other treatment options on the horizon.
Andre Goy, MD, Appointed Physician-in-Chief to Lead Cancer Care Across Hackensack Meridian Health Network
June 18, 2020
Article
Hackensack Meridian Health has announced the appointment of Andre Goy, MD, MS, as physician-in-chief of the Hackensack Meridian Health Oncology Care Transformation Service.
Dr. Goy on the Evolution of Treatment Selection in MCL
May 13, 2020
Video
Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.
PET Scans and Novel Therapies Propel Progress in Hodgkin Lymphoma
May 13, 2020
Article
Tatyana Feldman, MD, discusses the significance of PET-adapted strategies in Hodgkin lymphoma, novel therapies that have emerged in the pipeline, and where future research is headed.